Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplanation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
Duration: November 13, 2007
to
September 23, 2011
General Issues: Health Issues , Medicare/Medicaid , Pharmacy
Spending: about $450,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2007: House of Representatives, U.S. Senate, U.S. Senate,
Related Foreign Entities:
Astellas Pharma, Inc. (Tokyo, JPN); contribution to lobbying: $0; ownership 99%
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2011
CAPITOL HILL CONSULTING GROUP terminated an engagement in which they represented Astellas Pharma US on Oct. 5, 2011.
Original Filing: 300410925.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplanation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2011
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on July 13, 2011.
Original Filing: 300389361.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplanatation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues including, but not limited to, coverage and reimbursement of pharmaceuticals
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2011
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on April 19, 2011.
Original Filing: 300370165.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; Patient Protection and Affordable Care Act (P.L. 111-148); Prescription Drug User Fee Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
General Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement of pharmaceuticals
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2010
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on Jan. 19, 2011.
Original Filing: 300346402.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; STARR Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of immunosuppressants
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q32010 on Oct. 19, 2010.
Original Filing: 300318040.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; STARR Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of immunosuppressants; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R. 3950)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2010
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on Oct. 14, 2010.
Original Filing: 300313175.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and health care associated infections and organ transplantation; STARR Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Health Care Act (H.R.3950)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2010
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on July 14, 2010.
Original Filing: 300286468.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STARR Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2010
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on April 19, 2010.
Original Filing: 300266471.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STARR Act; Drug Importation; Follow-on Biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of immunosuppresants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S.565); American's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R. 3862); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2009
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on Jan. 8, 2010.
Original Filing: 300228332.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STARR Act; Drug Importation; Follow-on Biologics
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (H.R. 1458/S. 565); America's Affordable Health Choices Act (H.R. 300); America's Healthy Future Act of 2009; Affordable Healthcare for America Act (H.R.3862); Patient Protection and Affordable Care Act (H.R. 3590)
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q32009 on Dec. 11, 2009.
Original Filing: 300226238.xml
Lobbying Issues
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STAAR Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR1458/S.565); America's Affordable Health Choices Act (HR3200); America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2009
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on Oct. 7, 2009.
Original Filing: 300201279.xml
Lobbying Issues
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation; STAAR Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
issues related to Medicare coverage of immunosuppressants; Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act (HR1458/S.565); America's Affordable Health Choices Act (HR3200); America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q22009 on Dec. 11, 2009.
Original Filing: 300226237.xml
Lobbying Issues
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
issues related to: Medicare coverage of immunosuppressants; Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act HR1458/S.565
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2009
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on July 14, 2009.
Original Filing: 300176441.xml
Lobbying Issues
issues pertaining to antimicrobial resistance; community and healthcare associated infections and organ transplantation
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
issues related to: Medicare coverage of immunosuppressants; Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act HR1458/S.565
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q12009 on Dec. 11, 2009.
Original Filing: 300226236.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Ace of 2007
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2009
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on April 14, 2009.
Original Filing: 300147653.xml
Lobbying Issues
Issues pertaining to antimicrobial resistance; Issues pertaining to community and healthcare associated infections; Issues pertaining to organ transplantation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Ace of 2007
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q42008 on Dec. 10, 2009.
Original Filing: 300226225.xml
Lobbying Issues
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; , Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007
Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005; S. 3560, QI Program Supplemental Funding Act of 2008 -- the QI bill included language to protect critical medications
under Part D originally in H.R. 6331/S. 1887.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q42008 on Jan. 16, 2009.
Original Filing: 300122011.xml
Lobbying Issues
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; , Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act, S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007
Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005; S. 3560, QI Program Supplemental Funding Act of 2008 -- the QI bill included language to protect critical medications
under Part D originally in H.R. 6331/S. 1887.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2008
In Q4, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on Jan. 14, 2009.
Original Filing: 300117423.xml
Lobbying Issues
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; S. 1887, Medicare Access to Critical Medications Act and HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act; S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007
Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q32008 on Dec. 10, 2009.
Original Filing: 300226224.xml
Lobbying Issues
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, Animal Drug User Fee Amendments Act of 2008; S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; S. 1887, Medicare Access to Critical Medications Act and
HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act
S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007
Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2008
In Q3, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on Oct. 17, 2008.
Original Filing: 300096817.xml
Lobbying Issues
Issues related to: Antibiotic exclusivity and Infectious disease control; H.R. 6432, Animal Drug User Fee Amendments Act of 2008; S. 2313 and H.R. 3697, the Strategies to Address Antimicrobial Resistance (STAAR Act); S. 3560, QI Program Supplemental Funding Act of 2008; S Res 454 and H Res 988, designating March 2008 as MRSA Awareness Month
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to: Medicare coverage of immunosuppressants, Medicare Part D's six classes of clinical concern, Medicaid payment for hospital-acquired conditions; The Medicare Improvements for Patients and Providers Act Technical Corrections Act; S. 1887, Medicare Access to Critical Medications Act and
HR 3061, Amending Title XVIII of the SSA to ensure access to critical medications under Medicare Part D; S. 1951 and H.R. 3700, the Fair Medicaid Drug Payment Act
S. 2320 and H.R. 3282, the Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007
Issues related to implementation of Section 5001(c) of the Deficit Reduction Act of 2005
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q22008 on Dec. 10, 2009.
Original Filing: 300226223.xml
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: coverage and reimbursement issues under the Medicare and Medicaid programs
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q22008 on July 16, 2008.
Original Filing: 300067374.xml
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: coverage and reimbursement issues under the Medicare and Medicaid programs
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; and drug safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2008
In Q2, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on July 9, 2008.
Original Filing: 300062071.xml
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: coverage and reimbursement issues under the Medicare and Medicaid programs
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatch-Waxman Act; drug importation; and drug safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
CAPITOL HILL CONSULTING GROUP amended a lobbying report for representation of Astellas Pharma US in Q12008 on Dec. 10, 2009.
Original Filing: 300226220.xml
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: Coverage and reimbursement issues under the Medicare and Medicaid programs
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatchwaxman Act; drug imporation; and drug safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2008
In Q1, CAPITOL HILL CONSULTING GROUP lobbied for Astellas Pharma US , earning $30,000. The report was filed on April 16, 2008.
Original Filing: 300038404.xml
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to, federal organ transplant and anti-infectives policy
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: Coverage and reimbursement issues under the Medicare and Medicaid programs
Agencies Lobbied
U.S. House of Representatives U.S. Senate,
Lobbying Issues
Pharmaceutical and life sciences, including but not limited to: The Federal Food, Drug and Cosmetic Act; the Hatchwaxman Act; drug imporation; and drug safety
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2007
Capitol Hill Consulting Group filed a lobbying registration on Dec. 9, 2009 to represent Astellas Pharma US, effective Nov. 13, 2007.
Original Filing: 300226202.xml
Issue(s) they said they’d lobby about: Pharmaceutical and life sciences, including but not limited to:
The Federal Food, Drug and Costmetic Act; Coverage and reimbursement issues under the Medicare and Medicaid programs; Drug importation; Follow-on biologics (i.e., the Pharmaceutical Biologics Price Competition and Innovation Act of 2007); federal organ transplant and anti-infectives policy .
4th Quarter, 2007
Capitol Hill Consulting Group filed a lobbying registration on Feb. 10, 2008 to represent Astellas Pharma US, effective Nov. 13, 2007.
Original Filing: 300013171.xml
Issue(s) they said they’d lobby about: Pharmaceutical and life sciences, including but not limited to:
The Federal Food, Drug and Costmetic Act; Coverage and reimbursement issues under the Medicare and Medicaid programs; Drug importation; Follow-on biologics (i.e., the Pharmaceutical Biologics Price Competition and Innovation Act of 2007); federal organ transplant and anti-infectives policy .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate